Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Consumer Health · Haleon Taiwan
№ 94 · The Haleon Taiwan dossier

Haleon Taiwan

Haleon 台灣
Parent: Haleon plc (LSE: HLN; NYSE: HLN) — spun off from GSK July 2022
Readiness
60
Greenfield
Capped at 95. High confidence — AOR sourced within 0y · high-confidence research.
Workspace · saved locally in your browser
Pipeline status
Your notes · Haleon Taiwan
Saves on blur. Stored in your browser only — not synced.

Consumer health spin-off (GSK Consumer Healthcare → LSE July 2022). Post-Oct 2025 review: WPP leads wellness + oral health globally (Sensodyne is the flagship), Publicis leads OTC pain + cold/flu (Voltaren, Panadol, Advil). Regional cluster ownership (SEA + TW). Heavy pharmacy/Watsons/Cosmed channel in TW. Sensodyne is the most marketed brand globally and likely in TW.

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 60
score breakdown
Intel depth (6 wedges · M&A, recent, transformation)research_depth+60
Total · capped 9560
30-day signal trajectory
0 signals · spend N/A
Intel wedges
6/8
6 of 8 wedges corroborated. Research confidence: high — Oct 2025 WPP/Publicis split is publicly documented across AdAge, Campaign Live, MediaPost, Storyboard18. TW-local nuance is medium-confidence..
Open playbook →
Recommended posture
Watch closely.
WPP just WON Sensodyne + Aquafresh + wellness globally in Oct 2025 — this is the strongest WPP-defend/expand pitch surface in this batch. Sensodyne TW activation falls under WPP Media TW scope by inheritance.